OxyNEO – Changes to ODB Formulary

The Ministry of Health and Long-Term Care provide answers to frequently asked questions about the introduction of OxyNEO and resulting changes to the Ontario Drug Benefit Formulary.

Questions & Answers

What is the Ontario Drug Benefit (ODB) funding status of OxyContin and OxyNEO?

Effective February 29, 2012, the ministry will remove OxyContin from the Ontario Drug Benefit Formulary/Comparative Drug Index (“ODB Formulary”). The funding for oxycodone controlled release tablet will be changed from its current Limited Use listing to the Exceptional Access Program (EAP). Exemptions are provided for physicians participating in the Facilitated Access to Palliative Care Drugs mechanism. There will also be a one-year transition period for patients currently receiving OxyContin. Details are provided below.

Existing ODB recipients of OxyContin:
ODB recipients who have had a claim submitted to the ODB program for OxyContin between September 1, 2011 and February 28, 2012, will receive automatic coverage for OxyContin for another month. All coverage for OxyContin will cease on April 2, 2012. In addition, these patients will receive automatic coverage for OxyNEO (10mg, 15mg, 20mg, 30mg, 40mg and 80mg) for a period of one year (February 29, 2012 to February 28, 2013).

If coverage for OxyNEO is required beyond February 28, 2013, an EAP approval will be required. (Please see EAP criteria for OxyNEO below.)

Prescribers are asked to note that the current turnaround time for EAP requests is approximately three months. For patients in whom OxyNEO continues to be an appropriate therapy, it is recommended that prescribers submit EAP requests to the ministry at least three months in advance of February 28, 2013. The ministry will send out reminder notices throughout the year.

All other ODB patients requiring OxyNEO:
For all other ODB patients requiring oxycodone controlled release tablet starting February 29, 2012, OxyNEO will be funded as follows:

(1) Exceptional Access Program (EAP)
OxyNEO 10mg, 15mg, 20mg, 30mg and 40mg tablets will be considered through the EAP for patients with chronic pain according to the following criteria:

New Patients
For the treatment of chronic pain in patients who have experienced intolerance or have failed an adequate trial (for example, three months) of at least one other listed long-acting opioid product; AND

Physicians should consider best practice guidelines for the safe and effective use of opioids in chronic non-cancer pain, such as the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain (available at: http://nationalpaincentre.mcmaster.ca/opioid).
• The diagnosis for which the pain management is required must be documented;
• All concomitant pain medication therapy must be documented;
• Other medications with potential for abuse or interaction with opioid therapy should be documented.

Renewals
• Treatment continues to be appropriate for the management of the patient’s chronic pain.
• All concomitant pain medication therapy must be documented;
• Other medications with potential for abuse or interaction with opioid therapy should be documented.

Note: OxyNEO 60mg and 80mg tablets are not funded.

Approval period: one year (new and renewals)

(2) Facilitated Access to Palliative Care Drug Products (Part VI-b of the ODB Formulary)
OxyNEO 10mg, 15mg, 20mg, 30mg, 40mg and 80mg tablets for cancer patients or palliative care patients for whom the prescriber is registered on the Palliative Care Facilitated Access List will be funded with the following criteria:

For the treatment of cancer-related pain, or pain in patients receiving end-of-life palliative care; AND

The patient has experienced intolerance or has failed an adequate trial (for example, three months) of at least one other listed long-acting opioid product.

Note: For reimbursement of OxyNEO via the Facilitated Access mechanism, prescribers must be registered on the Palliative Care Facilitated Access List. To facilitate the reimbursement process at the pharmacy, the prescriber is asked to indicate “Cancer”, “Palliative” or “P.C.F.A.”, on the prescription to signify that the patient meets the above-noted eligibility criteria. This would be an indication to the pharmacist that these medications may be reimbursed under this mechanism.

Note: If the prescriber is not registered on the Palliative Care Facilitated Access List, a request for funding of OxyNEO must be made through the EAP process based on the EAP criteria noted above.

Note: OxyNEO 60mg tablets are not funded.

Approval period: one year

Additional information on the Facilitated Access Mechanism can be found on Part VI of the ODB Formulary.
Why is the ministry making the Ontario Drug Benefit (ODB) funding of oxycodone controlled release tablet more restrictive?

Recent studies suggest that increased rates of opioid prescribing, particularly oxycodone, is contributing significantly to opioid-related harms and deaths. Issues identified in these studies include excessive prescribing, escalating misuse, escalating diversion of drugs away from intended medical purposes, increases in addictions, and increases in opioids-related deaths.

Ontario has the highest rate of narcotics use in Canada. Between 1991 and 2009, the number of prescriptions in Ontario for oxycodone drugs rose by 900 per cent. Each year in Ontario, between 300 and 400 people die from overdoses involving prescription opioids. The opioid most commonly found on post-mortem analyses in recent years is oxycodone.

Furthermore, analyses conducted by the ministry on the prescribing and utilization of oxycodone controlled release tablets through the ODB Program found that the majority of utilization of this drug is outside the current Limited Use criteria.

With the introduction of OxyNEO, the ministry consulted its expert advisory committee, the Committee to Evaluate Drugs (CED), on how the ODB Program should fund this drug. The CED noted that while the new OxyNEO formulation is reported to be more tamper-resistant, concerns remain about the safety of OxyNEO and the significant potential for misuse or overuse by ingesting the tablet whole. The CED noted that listing OxyNEO as a Limited Use benefit will make it more easily accessible and allow for continued misuse or overuse resulting in opioid-related harm, similar to that observed with OxyContin. The CED recommended that OxyNEO be funded through the Exceptional Access Program (EAP) according to specific criteria.

Based on the CED’s recommendation and discussions with pain specialists, addiction experts and other health care professionals, the ministry decided to move forward with a restricted funding of OxyNEO as outlined above.

The ministry anticipates that taking steps to change the funding status of oxycodone controlled release tablets will serve to improve the quality and value of the overall health and safety of patients and the public.

The ministry will continue to monitor the utilization of oxycodone and other opioids to determine if further actions and changes would be required.

What is the Exceptional Access Program?

The Exceptional Access Program (EAP) facilitates patient access in exceptional circumstances to drugs not listed on the Formulary or where Formulary drugs were ineffective, not tolerated, or where no listed alternative was available. To apply through the EAP, a physician must submit a request documenting complete and relevant medical information to the ministry, and provide the clinical rationale for requesting the unlisted drug and reasons why covered benefits are not suitable. All requests are reviewed according to the guidelines recommended by the CED and approved by the Executive Officer, and include a thorough assessment of the patient’s specific case and clinical circumstances, as provide by the physician, as well as the available scientific evidence.
For more information about the EAP, please visit the ministry website at: http://www.health.gov.on.ca/english/providers/program/drugs/eap_mn.html

**What is the Facilitated Access mechanism?**

Specific products used to treat ODB-eligible patients undergoing palliative care are reimbursed under the Ontario Public Drug Programs, through its Facilitated Access process. Under this process, a select group of participating physicians are exempt from obtaining approval under Exceptional Access Program (EAP).

In order to participate in the Facilitated Access to Palliative Care Drugs process, physicians must be registered by the Ontario Medical Association (OMA) and must meet pre-defined criteria the OMA sets.

Physicians who are not registered through this process must obtain approval through the EAP.

For further information regarding the list of physicians and/or the criteria physicians require to be included on the list, please contact Dr. Howard Burke, c/o Ina Nesbitt, Ontario Medical Association: (416) 340-2234, or via email at Ina_Nesbitt@oma.org.

**Why are the 60mg and 80mg strengths of OxyNEO not being funded through the Exceptional Access Program (EAP)?**

The ministry noted that the "watchful dose" recommended in the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain is 200mg/day morphine equivalent. The guideline states that “the potential for adverse psychological and physical effects, the potential for misuse, and questionable efficacy are all factors that should be considered in limiting the dose and increasing the frequency of follow-up visits. Some studies reported safety concerns or questionable efficacy of higher daily doses of opioids.” (http://nationalpaincentre.mcmaster.ca/opioid)

As part of the review for OxyNEO, the Committee to Evaluate Drugs (CED) noted that the 60mg and 80mg strengths, when used twice daily, would be approximately the same or exceed this watchful dose. The CED also noted that in a trial by Portenoy et al (Clin J Pain 2007;23:287-299), the mean daily dose of oxycodone controlled release tablet was 52.5mg for the treatment of non-cancer pain. This further demonstrates that use of the 60mg and 80mg tablets would exceed the dosage amount typically required for non-cancer pain. Because of these concerns and the availability of alternative opioids on the OBD Formulary, the CED recommended that the 60mg and 80mg strengths of OxyNEO not be funded for chronic non-cancer pain.

**If a patient has a prescription for OxyContin, is the pharmacist able to interchange/substitute the prescription for OxyNEO?**

No. In Ontario, OxyNEO and OxyContin have not been designated as interchangeable with one another. Therefore, a new prescription for OxyNEO would be required in this case.

**What is the pharmacy process for submitting Ontario Drug Benefit (ODB) claims for OxyNEO?**

If the patient has an EAP approval for OxyNEO, an ODB claim can be submitted through the normal process.
If the patient is receiving OxyNEO through the Facilitated Access (FA) mechanism, the dispenser must use the PINs outlined below when submitting the claim. When an FA claim is submitted, the Health Network System will validate the prescriber identification (through the prescriber’s licence number).

<table>
<thead>
<tr>
<th>PIN</th>
<th>Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>09857408</td>
<td>OxyNEO 10mg CR Tab</td>
</tr>
<tr>
<td>09857409</td>
<td>OxyNEO 15mg CR Tab</td>
</tr>
<tr>
<td>09857410</td>
<td>OxyNEO 20mg CR Tab</td>
</tr>
<tr>
<td>09857411</td>
<td>OxyNEO 30mg CR Tab</td>
</tr>
<tr>
<td>09857412</td>
<td>OxyNEO 40mg CR Tab</td>
</tr>
<tr>
<td>09857413</td>
<td>OxyNEO 80mg CR Tab</td>
</tr>
</tbody>
</table>

To facilitate the reimbursement process at the pharmacy, the prescriber is asked to indicate “Cancer”, “Palliative” or “P.C.F.A.”, on the prescription to signify that the patient meets the above-noted eligibility. This would be an indication to the pharmacist that these medications may be reimbursed under this mechanism. A list of prescribers currently registered through the Facilitated Access to Palliative Care Drugs process will be sent to pharmacist through the OneMail system.